Salute e Benessere

Compass Pathways announces investigational COMP360 psilocybin treatment was…

Initial safety findings at 24 hours post dosing were consistent with studies of COMP360 in other psychiatric conditions The open-label study evaluated the safety and tolerability of COMP360 psilocybin treatment in patients with PTSD as a result of trauma experienced as adults. 22 participants received a single 25mg dose of investigational COMP360 psilocybin treatment. The initial data readout, based on monitoring patients at 24 hours post COMP360 administration, indicated that COMP360 was...
Nasdaq GlobeNewswire
19/12/2023

Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of…

Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 study to evaluate the safety, efficacy, and feasibility of our seven-day vein-to-vein, point-of-care manufactured BCMA CAR-T candidate, GLPG5301, in adult patients with relapsed/refractory multiple myeloma (rrMM). This is Galapagos' third oncology CAR-T program in clinical development. GLPG5301 is an autologous,...
Nasdaq GlobeNewswire
19/12/2023

New study finds the majority of cancer patients use online resources at least…

Specifically, patients reported that their own life goals and preferences were not systematically discussed during treatment: Specifically, patients reported that their own life goals and preferences were not systematically discussed during treatment: At the same time, many patients were not presented with the latest, evidence-based options to guide their treatment choices. For example: only 28% of patients were alerted to clinical trials as a treatment option, despite the fact that clinical...
PR Newswire
19/12/2023

ENDO FILES PLAN OF REORGANIZATION TO IMPLEMENT PREVIOUSLY ANNOUNCED SALE…

The Plan is a preferred alternative to the previously announced sale of substantially all the Company's assets to holders of Endo's first lien debt (the "Ad Hoc First Lien Group") under Section 363 of the U.S. Bankruptcy Code, with substantially similar terms: a purchase of substantially all of the Company's assets via a credit bid of existing first lien debt, the assumption of certain liabilities, and offers of employment to all of Endo's active team members. This ownership transfer…
PR Newswire
19/12/2023

Ankle Fusion Nail Market Size to Surpass US$ 1,145.2 Million by 2030 -…

Market Trends: Market Trends: There are two prominent trends in the Ankle Fusion Nail market. Firstly, there is a growing preference for minimally invasive surgeries, which offer reduced scarring, faster recovery times, and better patient outcomes. This trend is driven by the advancements in surgical techniques and the development of innovative ankle fusion nail devices. Secondly, there is an increasing focus on patient-specific implants and personalized treatments in orthopedic surgeries,...
PR Newswire
19/12/2023

Abzena partners with FDA on publication demonstrating the benefits of the MAPPs…

Abzena has over 20 years of experience in developing phase-appropriate assays for the assessment of potency, efficacy, and safety. Demonstrated to be an effective tool in de-risking biologics in early preclinical stages and offering significant benefits over traditional immunogenicity assays, Abzena has integrated the MAPPs assay into its extensive immunogenicity service offering. Abzena has over 20 years of experience in developing phase-appropriate assays for the assessment of potency,...
PR Newswire
19/12/2023

Ultimovacs ASA: Mandatory notification of trade by primary insider

This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading Act. Attachment 20231219 - Ultimovacs Notification of trade - CDS - KRT 1500
Nasdaq GlobeNewswire
19/12/2023

Global MedTech Industry Outlook 2024 - Exclusive Report by MarketsandMarkets™

Inquire Now: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=64921163 Inquire Now: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=64921163 The MedTech Industry Outlook 2024 is structured to provide: Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64921163 The MedTech Industry Outlook 2024 report is an insightful toolkit for incumbent market participants, tech players, SME's, the investment community as well...
PR Newswire
19/12/2023

Clinical Alarm Management Market Worth $5.4 billion | MarketsandMarkets

Browse in-depth TOC on "Clinical Alarm Management Market" Browse in-depth TOC on "Clinical Alarm Management Market" 292 - Tables 55 - Figures 319 - Pages Clinical Alarm Management Market Scope: "Consulting & Implementation Services segment accounted for the largest share of the global Clinical alarm management market, by services." Based on the type of services, the clinical alarm management market is bifurcated into consulting & implementation, training...
PR Newswire
19/12/2023

FDA grants priority review to Xolair (omalizumab) for children and adults with…

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study showed Xolair significantly increased the amount of peanut, milk, egg and cashew it took to cause an allergic reaction17 million people in the U.S. have confirmed food allergies and more than 40% of children and more than half of adults with food allergies have experienced a severe...
Nasdaq GlobeNewswire
19/12/2023

Philips completes cancellation of 15.1 million shares

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that it has completed the cancellation of 15,134,054 of its shares. The cancelled shares were acquired as part of the EUR 1.5 billion share repurchase program for capital reduction purposes that was announced on July 26, 2021. Philips will complete the share repurchase program in April 2024, which is expected to result in a further cancellation of 4.4 million shares in Q2 2024. Philips' current issued...
Nasdaq GlobeNewswire
19/12/2023

Evaxion Biotech Announces Private Placement Financing

MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, is contributing with some 25% of the total offering amountCompany's management and board of directors with significant participation in the total offeringCOPENHAGEN, Denmark, Dec.19, 2023(GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...
Nasdaq GlobeNewswire
19/12/2023

Parexel Recognized with Frost & Sullivan's 2023 North American Customer Value…

Parexel leverages its in-depth RWE knowledge to identify evidence gaps and formulate evidence-generation strategies. The company brings extensive expertise in strategic and operational consulting, clinical development, regulatory affairs and market access to help ensure the successful design, implementation, execution and analysis of diverse RWE studies. Parexel leverages its in-depth RWE knowledge to identify evidence gaps and formulate evidence-generation strategies. The company brings...
PR Newswire
19/12/2023

HERVOLUTION Therapeutics Appoints Biotech Builder J. Robert Coleman as CEO to…

Dr Coleman co-founded and was CEO of Codagenix where he secured up to $498M in public and private financing to support early and late-stage development of viral-based vaccines and therapeutics - understanding all aspects of manufacturing, regulatory, and clinical design. His skillset is advancing groundbreaking preclinical discoveries into first-in-human proof of concept trials and beyond; thus, Coleman's expertise aligns seamlessly with HERVOLUTION's mission. Dr Coleman co-founded and was…
PR Newswire
19/12/2023

Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are…

BiogenInc. (Nasdaq: BIIB) today announced that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen's product TECFIDERA® (dimethyl fumarate) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva. In reaching this decision, the European Commission affirmed that Biogen is entitled to full data protection and marketing protection for TECFIDERA. Biogen welcomes the actions of the European Commission, which confirm the laws governing data...
Nasdaq GlobeNewswire
19/12/2023

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy…

~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history of the disease ~ ~ Mean CSF NfL continue to demonstrate favorable trends with low-dose patients below baseline at 30 months and high-dose patients near baseline at 18 months ~~ AMT-130 continues to be generally well-tolerated across both doses ~~ Data support continuing clinical...
Nasdaq GlobeNewswire
19/12/2023

Burjeel Holdings Oncology Conference Marks 10 Years, Focusing on Equitable…

Dr. Catharine Young, Assistant Director for Cancer Moonshot Engagement and Policy at the White House, highlighted the importance of collaboration and innovation in achieving the Cancer Moonshot's ambitious goal of a 50% reduction in cancer deaths within 25 years. Dr.Catharine Young, Assistant Director for Cancer Moonshot Engagement and Policy at the White House, highlighted the importance of collaboration and innovation in achieving the Cancer Moonshot's ambitious goal of a 50% reduction in...
PR Newswire
19/12/2023

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced “first patient dosed” in its Phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS). Six investigational centers have been recruited for this double-blind, placebo-controlled trial, with up to 18 patients per treatment arm. The primary endpoint of the trial will be...
Nasdaq GlobeNewswire
19/12/2023

LTS receives $4.3 Million grant for the development of contraceptive Microneedle…

MAPs are an innovative drug delivery technology that offers advantages in comparison to established drug delivery applications for contraception such as fewer side effects and potentially improved bioavailability with therapeutic and cost benefits. The MAP contraceptive is planned as a long-acting application (6 month). In comparison to other existing long-acting forms it can be self-administered, is discreet and does not require healthcare provider visits. MAPs are an innovative drug…
PR Newswire
19/12/2023

Daniel Graf joins Aktiia as the new President and Independent Board Member

About Aktiia About Aktiia Aktiia was founded inSwitzerlandinMay 2018out of a passion to create the best tool for diagnosis and treatment of hypertension. Aktiia's founders,Mattia Bertschi(CEO) and Josep Solà (CTO), contributed to research and development at CSEM, a prestigious Swiss research institute. For 15 years they worked incessantly to decipher the language of the heart to deepen our understanding of blood pressure. Aktiia's diverse team of 40 extraordinary people has...
PR Newswire
19/12/2023

Cutting-Edge Gut Microbiome Research: NOSTER's latest solutions for…

Noster analytics websitehttps://www.noster.inc/services/ Noster analytics websitehttps://www.noster.inc/services/ Noster's microbiome analysis approach simultaneously evaluates the composition of gut bacteria and its metabolite profile through a fusion of metagenomics and metabolomics. Metagenomics involves analyzing the genetic information of gut microbiota, while metabolomics addresses the properties of metabolites produced by the gut microbiome. By integrating these methodologies,...
PR Newswire
19/12/2023

Major shareholder announcement from Burlington Loan Management DAC

December 19, 2023 – Company announcement no. 12 Please see attachment. Contact informationInvestor RelationsDisa Tuominen +45 6038 5826dkditu@chr-hansen.comPress RelationsSanne Seyer-Hansen +45 6038 6207dksash@chr-hansen.com About Chr. Hansen Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen, we are strongly...
Nasdaq GlobeNewswire
19/12/2023

Hospital in Germany Orders Nexstim NBS System 5

Press release, Helsinki, 19 December 2023 at 11 AM (EET)Hospital in Germany Orders Nexstim NBS System 5 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 5 system from a hospital in Germany.Nexstim's NBS (Navigated Brain Stimulation) System 5 is CE marked and FDA approved for presurgical mapping of the speech and motor cortices of the brain. In addition to its motor and speech mapping features, this specific system also includes therapeutic...
Nasdaq GlobeNewswire
19/12/2023

BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Juliusz Rakowski

BBS-Bioactive Bone Substitutes Plc, Company announcement, Management transactions, 19 December 2023 at 10.30 a.m. (EEST)BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Juliusz Rakowski ____________________________________________Person subject to the notification requirementName: Rakowski, JuliuszPosition: CEOIssuer: BBS-Bioactive Bone Substitutes OyjLEI: 743700BYSBP0PCR6N767Notification type: INITIAL NOTIFICATIONReference number:...
Nasdaq GlobeNewswire
19/12/2023
Altri  Comunicati